Skip to main content

Table 1 Clinical characteristics of the patients with endoscopically suspected Barrett’s esophagus ≥ 1 cm

From: Association between obesity and Barrett’s esophagus in a Japanese population: a hospital-based, cross-sectional study

  PPI non-users PPI users
  Controls ESBE ≥ 1 cm P Controls ESBE ≥ 1 cm P
Number 840 (69.2) 68 (5.6) - 256 (69.8) 23 (6.3) -
  SIM - 19/49 (38.8) - - 8/18 (44.4) -
Patients profile       
  Age, y 56.2 ± 14.8 58.3 ± 13.6 0.31 63.5 ± 15.3 67.5 ± 12.4 0.26
  Male sex 464 (55.2) 47 (69.1) 0.03 129 (50.4) 14 (60.9) 0.34
  Alcohol drinking 244 (29.0) 20 (29.4) 0.95 54 (21.1) 8 (34.8) 0.13
  Current smoking 173 (20.6) 14 (20.6) 0.99 34 (13.3) 3 (13.0) > 0.99
  GERD symptoms 126 (15.0) 12 (17.6) 0.56 74 (28.9) 9 (39.1) 0.30
Endoscopic findings       
  Reflux esophagitis 68 (8.1) 17 (25.0) <0.0001 22 (8.6) 8 (34.8) 0.0001
  Gastric atrophy (Open-type) 158 (18.8) 16 (23.5) 0.34 96 (37.5) 6 (26.1) 0.28
  1. PPI proton pump inhibitor, ESBE endoscopically suspected Barrett’s esophagus, SIM specialized intestinal metaplasia, GERD gastroesophageal reflux disease, NS not significant.